Reports FY22 adjusted EBITDA ($286.3M) vs. ($228.9M) y/y. "Our team’s commitment and hard work delivered outstanding health outcomes and an unmatched patient experience leading to consistent center-level performance and strong full year results. We remain committed to improving the well-being of our patients, bringing new patients to the Oak Street model, and rebuilding healthcare as it should be," said Mike Pykosz, CEO.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OSH:
- Oak Street Health downgraded to Neutral from Overweight at JPMorgan
- Oak Street Health downgraded to Market Perform from Outperform at Bernstein
- Oak Street Health downgraded to Market Perform from Outperform at Raymond James
- CVS Health price target raised to $143 from $130 at Jefferies
- Oak Street Health downgraded to Hold from Buy at Jefferies
